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ACADESINE: A NEW DRUG 
THAT MAY IMPROVE 
MYOCARDIAL PROTECTION 
IN CORONARY ARTERY 
BYPASS GRAFTING 
Results of the first 
international multicenter 
study 
The effect of acadesine, an adenosine-regulating a ent, on the incidence of 
myocardial infarction, all adverse cardiovascular outcomes (myocardial 
infarction, cardiac death, left ventricular dysfunction, life-threatening 
arrhythmia, or cerebrovascular accident) and mortality was assessed in 821 
patients undergoing coronary artery bypass grafting. Patients were pro- 
spectively stratified to a high-risk group (age >70 years, unstable angina, 
previous coronary bypass, unsuccessful angioplasty, or ejection fraction 
<30%) or a non-high-risk group. They were randomized in a double-blind 
manner to placebo (n = 418) or acadesine (n = 403) by intravenous 
infusion over 7 hours (0.1 mg/kg per minute) and in the cardioplegic 
solution (placebo or acadesine; 5 /xg/ml). Acadesine did not significantly 
affect the incidence of myocardial infarction in the overall study population, 
but it significantly reduced the incidence of Q-wave myocardial infarction 
in high-risk patients (placebo, 19.7%; acadesine, 10.0%; p = 0.032). The 
incidences of all adverse cardiovascular outcomes (placebo, 19.4%; 
acadesine, 18.4%) and overall mortality (placebo, 3.4%; acadesine, 2.7%) 
were similar between the two treatment groups. However, acadesine re- 
duced the incidence of cardiac related events that contributed to deaths 
occurring during the first 3 postoperative days so that the incidence of 
death in this period was lower (placebo, 1.9%; acadesine, 0.2%; p = 0.038). 
No adverse events were related to acadesine treatment. Although overall 
there were no statistically significant between-group differences for the 
primary study end points, a secondary analysis in a prospectively defined 
high-risk subgroup suggests that acadesine may be beneficial in some 
patients. (J THORAC CARDIOVASC SURG 1995;110:1096-106) 
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techniques and perioperative management. Several 
studies have demonstrated that older patients with 
more extensive coronary disease, poorer left ventric- 
ular function, and more comorbid diseases are now 
undergoing CABG and that these factors have a 
negative impact on morbidity and mortality) -8 In 
recent studies, representative of the current patient 
population undergoing CABG and surgical prac- 
tices being used, the mortality rate ranged from 3% 
to 8%. 1-3'9' 10 Cardiac events are still the most 
common causes of death after CABG, accounting 
for approximately 55% of the deaths, n Of these 
cardiac events, perioperative myocardial infarction 
(MI) is a significant complication of CABG, and its 
*The investigators and institutions participating in the Multina- 
tional Acadesine Study are listed in the appendix. 
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occurrence has been shown to have an adverse ffect 
on postoperative mortality rates and long-term sur- 
vival, a2-17 The prevalence of perioperative MI after 
CABG has been reported in the literature to range 
from 4% to 26%, depending on the criteria used for 
diagnosis.Z, 15, 17-3o The unequivocal recognition that 
the risk of morbidity and mortality associated with 
CABG can still be reduced has therefore led to the 
development of new strategies designed to preserve 
the myocardium by reducing ischemia and reperfu- 
sion injury. 31"3z Although some approaches have 
focused on the refinement of cardioplegic formula- 
tions, the tight control of reperfusate composition, 
or the search for the optimal route and technique of 
delivering cardioplegic solutions, an alternative ap- 
proach has consisted of supplying the myocardium 
with substrates or agents designed to reduce the 
extent of ischemia-reperfusion injury. In the latter 
case, however, the expected achievement of a ther- 
apeutic benefit has consistently relied on an exoge- 
nous supply of the purported cardioprotective 
agents. More recently, efforts have been focused on 
managing endogenous systems to lessen myocardial 
ischemia nd necrosis. Endogenous adenosine is an 
important mediator of myocardial preservation be- 
cause activation of adenosine receptors improves 
myocardial survival after ischemic insults (i.e., isch- 
emic preconditioning). 33 
Acadesine (5-amino-l-[/3-D-ribofuranosyl]imida- 
zole-4-carboxamide) belongs to a new class of agents 
called adenosine-regulating agents. These agents are 
believed to act by locally increasing the availability 
of adenosine only in tissues depleted of adenosine 
triphosphate (i.e., ischemia). 34-36 Several animal 
studies have now documented the cardioprotective 
effects of acadesine, including under conditions of 
global ischemic arrest, as occurs during CABG in 
human beings. 37' 38 In an initial small clinical trial in 
116 patients undergoing elective CABG, acadesine 
given intravenously and in cardioplegic solutions 
was shown to reduce the incidence of perioperative 
MI by 64% compared with placebo treatment. 39
Although the small sample size probably prevented 
attainment of statistical significance in this early study, 
the results were suggestive and provided the rationale 
for this larger, multinational randomized trial. 
Methods 
General study design. A double-blind trial was con- 
ducted in 821 patients with coronary artery disease. The 
patients were stratified by risk group and randomized in 
this placebo-controlled, parallel-group study. All were 
scheduled for elective, urgent, or emergency CABG and 
were enrolled at 27 medical centers in Europe and 
Canada (appendix). The protocol was approved by the 
ethics committee at each center. In accordance with the 
principles of the Helsinki Declaration, written informed 
consent was obtained from each patient. Patients received 
either placebo or acadesine administered intravenously 
for a total of 7 hours, beginning 15 minutes before the 
induction of anesthesia. The duration of infusion included 
the intraoperative (prebypass and postbypass) period and 
the immediate postoperative period in the intensive care 
unit for virtually all patients. The cardioplegic solution 
used for myocardial protection during cardiopulmonary 
bypass contained acadesine (final concentration of 5 /xg/ 
ml) or placebo, as appropriate to match the randomiza- 
tion for intravenous drug administration. An independent 
safety and data monitoring panel was responsible for 
decisions about the safe conduct and continuation of the 
trial. 
Patient selection. Patients were enrolled in the study 
between June 1991 and June 1992. Patients of either sex 
were eligible for recruitment. To be included in the 
study, patients were required to have coronary artery 
disease as assessed by coronary angiography, to have 
left main stenosis of at least 50% or stenoses of at least 
70% of two or more major coronary arteries, to be at 
least 35 years of age, and to be in hemodynamically 
stable condition at the time of the operation. Excluded 
from the study were the following: patients having valve 
replacement or hemodynamically significant valvular 
disease, patients with suspected or definite recent or_ 
evolving MI (within 7 days before the operation as 
evidenced by creatine kinase myocardial band [CK-MB] 
measures above the screening laboratory's reference 
range or changes in Q-wave morphology), or patients 
with a history of uric acid nephropathy or hyperurice- 
mia (serum uric acid value 20% above the institution's 
laboratory reference range), renal insufficiency (creat- 
inine concentration greater than two times the upper 
limit of the testing laboratory's reference range at the 
time of screening), or hepatic dysfunction (alanine 
aminotransferase or aspartate aminotransferase con- 
centrations greater than three times the upper limit of 
the testing laboratory's reference range at screening). 
Stratification, randomization, and treatment. Before 
randomization, patients were prospectively stratified into 
one of two groups: (1) high risk and (2) all other patients, 
termed non-high risk. The criteria defining high risk were 
age greater than 70 years, previous CABG, acute failure 
of percutaneous transluminal coronary angioplasty (with- 
out an evolving M1), unstable angina, and left ventricular 
dysfunction (ejection fraction <30%). Patients were ran- 
domly allocated within each center to treatment with 
placebo (Sterile Water for Injections, British Pharmaco- 
poeia) or acadesine (0.1 mg/kg per minute) according to a 
previously prepared computer-generated randomization 
code for each risk group. 
Adenosine, theophylline, aminophylline, pentoxifylline, 
and dipyridamole were not to be given for the 48 hours 
before the operation and during the first 48 hours after 
the operation because their presence might alter any 
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effects of acadesine. Intravenous nifedipine or other in- 
travenous calcium-channel antagonists were permitted, 
except as antiischemic prophylaxis. All other cardiovas- 
cular medications were continued, as indicated, until 
the operation. Anesthesia induction was limited to intra- 
venous fentanyl, alfentanyl, sufentanyl, midazolam, or 
propofol, according to local practice. Fluorinated inhala- 
tional agents were prohibited except for the use of isoflu- 
rane at one center. Operations were performed by means 
of standard techniques for myocardial revascularization. 
The type and method of administration of cardioplegic 
solutions were not controlled; however, cardioplegic solu- 
tions containing drugs other than the study drug (e.g., 
lidocaine) were not to be used. The use of warm blood 
cardioplegia was generally discouraged, although a subset 
of patients was treated with warm cardioplegia or with 
single warm blood terminal infusions ("hot shots"). One 
center used the surgical technique of intermittent aortic 
crossclamping without the use of any cardioplegic solu- 
tions. 
Outcome measurements and follow-up. The outcome 
measurements in this study were the incidence of fatal and 
nonfatal MI and the incidence of all adverse cardiovascu- 
lar outcomes (MI, cardiac death, severe left ventricular 
dysfunction, life-threatening arrhythmia, or cerebrovascu- 
lar accident). Outcomes were assessed for their occur- 
rence through ospital discharge. Follow-up for death and 
any other major adverse cardiovascular event was contin- 
ued for up to 12 months after the operation at 22 of the 27 
participating centers. 
Perioperative MI was diagnosed according to the fol- 
lowing criteria: (1) the presence of a new Q wave on 
postoperative twelve-lead electrocardiograms (ECGs) us- 
ing Minnesota code criteria 15 with clinical overreading; 
(2) elevation of serum CK-MB concentration to 100 ng/ml 
or more at any time after the operation, to 70 ng/ml or 
more at any time after 12 hours after the operation, or to 
12 ng/ml or more more than 24 hours after the opera- 
tion.ZV'4°'41; or (3) MI on autopsy. Twelve-lead ECGs 
were obtained at screening (within 7 days before the 
operation), on arrival in the intensive care unit, on 
postoperative days 1, 2, 3, and 4, and at hospital discharge. 
ECGs were transferred to a central site where they were 
coded and evaluated by a panel of blinded reviewers 
unaware of any other study data, comprised of a senior 
cardiologist and several coders. The senior cardiologist 
reviewed all sets of ECGs using standard ECG interpre- 
tive techniques to assess whether or not an MI had 
occurred. Two separate individuals independently as- 
signed Minnesota codes to each ECG and additionally 
reviewed each set using standard ECG interpretive tech- 
niques to assess whether a new Q-wave MI was present. 
ST-T wave changes unsupported by localized depolariza- 
tion abnormalities (e.g., new Q wave, deeper or wider Q 
wave) were not considered sufficient for the diagnosis of a 
perioperative MI. The panel, consisting of the senior 
cardiologist and all coders, reviewed each coded ECG set 
and agreed on the presence or absence of an MI for each 
patient. CK-MB concentrations were measured in serum 
samples obtained at screening and at 1, 4, 8, 12, 16, 20, 24, 
28, 32, 36, 42, 48, and 60 hours after removal of the aortic 
crossclamp. Processed serum samples were stored at 
-20°C at each site and then sent to the central abora- 
tory. The samples were stored at -20°C at the central 
laboratory until blinded analysis was performed by means 
of an immunoenzymetric assay kit (Tandem-E CKMB II, 
Hybritech [USA], San Diego, Calif.). Autopsy diagnosis of 
MI was made by the pathologist at each institution. 
Because of the complexity of diagnosing MI after 
CABG, MI may be defined by one or more of the criteria 
for diagnosis described earlier. Results are presented with 
less specific riteria (presence of a Q wave or elevation of 
CK-MB concentrations, or autopsy MI) used for the 
power calculation for this study, more specific riteria (Q 
wave and CK-MB, or autopsy MI), and by ECG and 
autopsy criteria alone (Q wave or autopsy MI). The latter 
secondary analysis was performed because the CK-MB 
data set was not considered completely reliable in this 
study; the CK-MB concentrations were lower than ex- 
pected, which is inconsistent with literature reports in the 
setting of CABG and the lack of CK-MB elevations in 
several patients with MIs proved at autopsy. Reasons for 
the questionable reliability of the CK-MB data set are 
discussed later. 
For patients who died, the cause of death was classified 
as to whether it was a primary cardiac death. Classifica- 
tions were determined by an independent panel of three 
cardiologists not associated with the clinical study, who 
were blinded to the patient's treatment assignment. Death 
occurring within the first 3 days after a CABG operation 
is considered acute11; therefore the effect of acadesine on 
mortality during this period was also assessed. 
Severe left ventricular dysfunction was considered 
present if cardiogenic shock (defined as a cardiac index 
<1.5 L/min per square meter and pulmonary capillary 
wedge pressure >20 cm for >1 hour) occurred or if an 
intraaortic balloon pump or left ventricular assist device 
for low output syndrome was required. 
Life-threatening arrhythmia was considered present if 
either of the following two criteria were met: (1) ventric- 
ular arrhythmia necessitating cardioversion, other than 
during bypass; and (2) conduction defect necessitating 
insertion of a permanent pacemaker. Cardioversion for 
atrial arrhythmias was not included in this definition of an 
adverse cardiovascular outcome. 
A cerebrovascular ccident was considered present if 
signs or symptoms of significant neurologic deficit per- 
sisted for more than 24 hours. Focal neurologic deficits 
associated with local nerve injury (e.g., local neuropathies 
produced by positioning during the operation) were not 
considered cerebrovascular ccidents. Patients with non- 
focal deficits were classified as having a cerebrovascular 
accident only when the diagnosis was confirmed by neu- 
rologic examination or when results from computed to- 
mographic scan or magnetic resonance imaging were 
consistent with a new cerebral infarct or hemorrhage. 
Statistical analysis. The sample size calculation of ap- 
proximately 400 patients per treatment group was made 
by the Lachin method, assuming two treatment groups 
and two outcomes (MI and no MI), with the underlying 
model being a 2 by 2 contingency table on which a X 2 test 
would be performed. 42The sample size was calculated to 
give a 90% chance of detecting a 33% reduction in the 
incidence of MI with a level of significance at 5%. The 
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placebo rate for the incidence of MI was set at 30%. A 
total of 53 strata, defined by combinations of 27 centers 
and two risk groups (one center had no high-risk patients), 
were used. Nine patients were assigned at study sites into 
the incorrect risk stratum. These patients were reclassified 
into the correct risk group for purposes of these analyses. 
All patients who received study drug and underwent 
CABG were included in the intent-to-treat nalysis. The 
comparability ofbaseline characteristics in the two treat- 
ment groups was assessed for discrete variables by the 
Pearson g 2 test or Fisher's exact est. Sparse data usually 
led to the use of Fisher's exact test. For continuous 
variables, analysis of variance techniques with rank trans- 
formation were used. For outcome measures, the Coch- 
ran-Mantel-Haenszel t st was used to compare the re- 
sponse for the two treatments. Control was imposed for 
stratum (center and risk group). When the data were 
too sparse to permit valid use of the Cochran-Mantel- 
Haenszel test, the strata were ignored and the incidences 
were compared by either the ~ test or Fisher s exact est. 
Additional logistic regression analyses were conducted to 
identify predictors of MI after adjusting for parameters of
surgical risk. 43 All reported p values are two sided and 
compare the two treatment groups. 
Results 
A total of 862 patients were screened for enroll- 
ment in the study. Of these, 41 patients did not enter 
the study and were considered nonparticipants. The 
remaining 821 patients were stratified by risk group, 
allocated to treatment assignment, and received 
study medication (placebo, n = 418; acadesine, n = 
403). The baseline characteristics of the two treat- 
ment groups were similar (Table I), and no signifi- 
cant differences in the extent of surgical exposure 
were detected (Table II). In addition, no statistically 
significant differences between treatment groups in 
the high-risk patients were noted for any of the 
baseline or surgical parameters. All patients were 
followed through discharge from the hospital; 
84% of the discharged patients (placebo, 339/405; 
acadesine, 328/392) received a follow-up examina- 
tion 4 to 5 weeks after the operation and 72% of 
patients completed the 6-month follow-up interval 
(placebo, 288/404; acadesine, 287/392). Data from 
only 59% of the patients (placebo, 237/402; 
acadesine, 231/391) were available at the 12-month 
follow-up survey. 
Morbidity resulting from adverse cardiovascular 
outcomes. The incidence of MI was not statistically 
different between the two treatment groups accord- 
ing to any of the criteria for diagnosis (Table III). 
However, acadesine significantly reduced the inci- 
dence of MI in the prospectively identified high-risk 
patients (placebo, 19.7%; acadesine, 10.0%; p = 
0.032) when MI was diagnosed by Q-wave or au- 
Table I. Baseline characteristics* 
Placebo Acadesine 
Characteristic (n = 418) (n = 403) 
Sex ratio, M/F (%) 83/17 84/16 
Mean age (yr)t 61.4 -4- 0.4 61.3 -4- 0.4 
Mean weight (kg) 76.1 _+ 0.6 75.9 _+ 0.6 
Cardiovascular history (%) 
Stable angina 90 89 
Previous MI 56 56 
Hypercholesterolemia 53 55 
Hypertension 43 41 
Unstable angina:~ 31 30 
Arrhythmias 12 12 
Previous PTCA 8 7 
Congestive heart failure 3 5 
Carotid bruit 5 4 
Previous CABG 3 4 
Valvular heart disease 2 3 
Risk group (%) 
Non-high risk 63 60 
High risk 37 40 
High-risk factor (%) 
Unstable angina§ 22 23 
Age >70 yr 18 17 
Previous CABG 3 4 
Ejection fraction <30% 4 3 
Acutely unsuccessful PTCA <1 0 
Preoperative catheterization 
->50% stenosis left main 18 16 
coronary artery (%) 
->70% stenosis of two or 93 94 
more coronary arteries 
(%) 
Mean No. of stenosed ves- 5.9 _+ 0.1 5.8 _+ 0.1 
selstt 
Mean % ejection fraction 56 _+ 1 58 _+ 1 
Mean LVEDP (mm Hg) 17 _ 1 17 - 1 
MI, Myocardial infarction; PTCA, percutaneous transluminal coronary 
angioplasty; CABG, coronary artery bypass grafting; LVEDP, left ventric- 
ular end-diastolic pressure. 
*No differences were statistically significant. 
?Mean -+ standard error. 
:~Any past history of unstable angina. 
§ Unstable angina was defined as (1) new-onset angina or progressively 
worse angina (increased frequency, intensity, or duration) that was less 
responsive to therapy within 7 days of CABG surgery or (2) angina t rest 
unresponsive to maximal therapy. 
[]Does not account for degree of stenosis. 
topsy criteria (Table IV). Unstable angina repre- 
sented the most frequently occurring risk factor 
among the high-risk patients. Univariate analysis of 
the incidence of MI by risk factor showed that 
acadesine treatment significantly reduced the inci- 
dence of MI in those high-risk patients with unstable 
angina as compared with patients receiving placebo 
(p = 0.002). No statistically significant differences 
were noted between the two treatments for the 
other individual risk factors. No clear evidence 
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Table II. Surgicalprofiles* 
Placebo Acadesine 
Procedure (n = 418) (n = 403) 
Mean No. of vessels grafted 3.2 3.2 
Type of graft (%) 
IMA and vein 69 74 
Vein only 19 17 
IMA only 12 9 
Mean duration of operation (min) 
Sternotomy to chest closure 197 202 
Before bypass t 124 127 
Bypass 97 96 
Crossclamp:~ (n) 55 (384) 55 (371) 
Intermittent crossclamp (n) 32 (32) 29 (32) 
After bypass§ 45 47 
Mean IV infusion (hr) 7.05 7.05 
Cardioplegia composition (%) 
Containing blood[[ 27 25 
Containing no blood 66 67 
No cardioplegia 7 8 
IMA, Internal mammary artery; IV, intravenous. 
*No differences were statistically significant. 
tTime from the start of infusion of study drug to start of bypass, 
:~Not available for two patients and excludes those patients with intermit- 
tent crossclamping. 
§Time from end of bypass to chest closure. 
IIUse of warm blood cardioplegic solutions was discouraged. 
could be found that treatment with acadesine 
showed any different effect on the basis of the 
number of vessels grafted or the type of cardioplegic 
solution used during bypass. 
No significant between-group difference in the 
incidence of the combined adverse cardiovascular 
outcomes was observed (Table III). The rate for 
each of the individual adverse cardiovascular out- 
comes other than MI was small, with no statistically 
significant differences between the treatments. The 
difference in the reductions observed for the indi- 
vidual outcomes compared with the incidence of 
combined adverse cardiovascular outcomes may be 
explained by the fact that twice as many patients in 
the placebo group (16/81) had more than one ad- 
verse cardiovascular outcome as compared with the 
acadesine group (7/74). 
The mean peak CK-MB level (78 + 11 ng/ml) 
observed for placebo-treated patients with a Q-wave 
MI was lower than expected as compared with 
reports of CK-MB levels measured with the same 
assay kit (Tandem-E CKMB II) in patients having 
CABG and subsequent MIs diagnosed by another 
modality (ECG, scintigraphy), z74`0, 44, 45 
Multivariate regression analyses were performed 
to evaluate the effect of acadesine on the incidence 
of MI (Q wave or autopsy) after adjusting for 
Table III. Incidences of adverse cardiovascular 
outcomes in total study population 
Placebo Acadesine 
(n = 418) (n = 403) 
P 
Outcome variable No. * % No. % Value 
MIt  
Q wave or CK-MB, 122/418 
or autopsy 
Q wave and CK-MB, 27/402 
or autopsy 
Q wave or autopsy 65/414 
Combined adverse car- 81/418 
diovascular out- 
comes:~ 
Cardiac death 7/418 
CVA 7/418 
Severe LV dysfunc- 14/418 
?ion 
Life-threatening ar- 12/418 
rhythmia 
29.2 108/403 26.8 NS 
6.7 20/385 5.2 NS 
15.7 51/399 12.8 NS 
19.4 74/403 18.4 NS 
1.7 5/403 1.2 NS 
1.7 5/403 1.2 NS 
3.3 13/403 3.2 NS 
2.9 9/403 2.2 NS 
MI, Myocardial infarction; NS, not significant; CK-MB, creatine kinase 
myocardial band; CVA, cerebrovascnlar accident; LV, left ventricular. 
*Number of patients/number of patients evaluable. 
?Diagnosis of a Q wave required ascreening ECG and a sufficient number 
of postoperative ECGs to allow clinical diagnosis; diagnosis by CK-MB 
criteria required at least two postoperative CK-MB determinations. 
~:MI (Q wave or autopsy), cardiac death, CVA, severe left ventricular 
dysfunction, or life-threatening arrhythmia. 
Table IV. Incidence of MI in high-risk subgroup 
Placebo Acadesine 
(n = 418) (n = 403) 
P 
MI * No. 7" % No. % Value 
High-risk subgroup 30/152 19.7 16/160 10.0 0.032 
Unstable Angina 25/93 26.9 10/91 11.0 0.002 
Age >70 yr 13/76 17.1 7/70 10.0 NS 
Previous CABG 3/12 25.0 1/18 5.6 NS 
EF <30% 3/16 18.8 1/12 8.3 NS 
Unsuccessful 1/1 100.0 0 0 - 
PTCA 
MI, Myocardial infarction; NS. not significant; CABG, coronary artery 
bypass grafting; EF, ejection fraction; PTCA, percutaneous transluminal 
coronary angioplasty. 
*Diagnosis by Q wave or autopsy. 
?Number of patients/number of patients evaluable. 
parameters ofsurgical risk, including type of cardio- 
plegia used, gender, history of severe left ventricular 
dysfunction, previous MI, or stratification to the 
high-risk subgroup. When this model was fit to all 
patients (both high-risk and non-high risk), there 
was a significant interaction between acadesine and 
risk group (p = 0.028) (Table V). Acadesine signif- 
icantly reduced the incidence of MI in high-risk pa- 
tients (odds ratio = 0.44, p = 0.015) but not in 
non-high-risk patients (odds ratio = 1.12, p = 0.665). 
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Table V. Logistic regression analysis for 
preoperative and operative risk factors* 
All patients High-risk patients 
(n = 805) (n = 309) 
Odds p Odds p 
Risk factor ratio Value ratio Value 
Acadesine 
Crystalline cardioplegia 
Blood cardioplegia 
Female 
Congestive heart 
failure 
Cardioplegia used 
Previous MI 
Acadesine, high risk§ll 
High risklJ 
0.44t 0.015 0.45 0.017 
1.12:~ 0.665 
0.81 0.635 0.72 0.624 
0.71 0.362 0.76 0.647 
0.93 0.793 0.78 0.548 
1.14 0.801 0.95 0.939 
1.20 0.756 1.14 0.873 
1.33 0.183 1.86 0.089 
0.39 0.028 
1.60 0.092 
MI, Myocardial infarction. 
*Patients had to be evaluable for MI (Q wave or autopsy) and all of the risk 
factors to be included in the analysis. 
tComparing acadesine to placebo in high-risk patients. 
:~Comparing acadesine to placebo in non-high-risk patients. 
§Interaction of acadesine and risk group. 
[fRisk factor not included in model for high-risk patients. 
High-risk patients had a higher MI rate than non-high- 
risk patients (odds ratio = 1.60,p = 0.092); and in the 
former group, acadesine treatment was the only factor 
that significantly reduced the incidence of MI (odds 
ratio = 0.45, p = 0.017). Other risk factors tested id 
not have a significant effect. Table V also presents the 
results obtained when this model was used only in the 
high-risk subgroup, which were consistent with those 
obtained for all patients. An interesting finding from 
this analysis was that prospectively defined high-risk 
patients with a previous MI had a greater isk for the 
occurrence of MI associated with CABG (odds ratio = 
1.86, p = 0.089) than did the overall population with a 
previous MI (odds ratio = 1.33, p = 0.183). 
Mortality. There were 25 deaths through the 4- 
to 5-week foUow-up period. Hospital mortality was 
not statistically different between the two groups 
(placebo 3.4%, 13/418; acadesine 2.7%, 11/403). 
One death in the placebo group was reported for the 
period between hospital discharge and the 4- to 
5-week follow-up visit. However, the number of 
deaths with acadesine treatment was significantly 
lower than with placebo (placebo 1.9%, 8/418; 
acadesine 0.2%, 1/403; p = 0.038) during the first 3 
postoperative days. It is noteworthy that periopera- 
tive myocardial insufficiency (manifest as low output 
syndrome usually associated with MI, arrhythmia, or 
severe ventricular dysfunction, which were reported 
as adverse vents) contributing to death was more 
Table VI. Cause of death 
Placebo Acadesine 
Cause of death (n = 418) (n = 403) 
Cardiovascular 13 9 
Myocardial insufficiency* 10 5 
Stroke 0 2t 
Other:~ 3 2 
Noncardiovascular 1 2 
All causes 14 11 
*Includes myocardial events uch as MI, arrhythmia, or severe ventricular 
dysfunction, which were considered to be major contributory factors 
ultimately leading to death. 
tRespiratory complications were also present. 
:]:Placebo: two mesenteric infarctions and one pulmonary embolism; 
acadesine: two hemorrhages. Of the patients dying of hemorrhage, one had 
retrosternal b eeding; the other patient (a Jehovah's Witness who refused 
blood transfusion) died of edema of the lung and respiratory insufficiency 
resulting from blood loss. 
prevalent in the placebo group than in the acadesine 
group (placebo 10/14; acadesine 5/11) (Table VI). 
The number of late deaths (5 to 52 weeks of 
follow-up) was similar for the two treatment groups 
(placebo 2/288; acadesine 2/287). 
Adverse experiences and laboratory evaluations. 
Acadesine was very well tolerated. The overall ad- 
verse experience rates for the placebo and 
acadesine-treated groups were identical (82%). 
Atrial fibrillation was the most frequently reported 
adverse vent in this study, but the rates were the 
same for both treatment groups (25%). No clinically 
significant differences were detected between 
acadesine and placebo treatment among other car- 
diovascular events: atrioventricular block, first- or 
second-degree (placebo 4.3%; acadesine 2.2%); 
heart block, third-degree (placebo 1.4%; acadesine 
1.2%); and hypotension (placebo 15.3%; acadesine 
20.3%). Hemodynamic measurements, including 
systolic and diastolic blood pressures and heart rate 
taken during the perioperative period, did not reveal 
any significant differences between the treatment 
groups. 
With the exception of mild, transient elevation of 
serum uric acid levels at the end of the acadesine 
infusion (27% above baseline level) (Fig. 1), there 
were no differences in clinical laboratory measure- 
ments between treatment groups. Elevations in uric 
acid concentration were transient and without clin- 
ical sequelae. 
Discussion 
Acadesine did not significantly affect the inci- 
dence of MI, defined by the presence of ECG and 
enzyme criteria or by autopsy; however, acadesine 
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Fig. 1. Percent change in uric acid concentration from baseline. POD, postoperative day; SE, standard error. 
significantly reduced the incidence of MI, defined 
only by ECG and autopsy criteria, in the prospec- 
tively defined high-risk patient group (p = 0.032). 
Although the incidence of hospital mortality was not 
reduced, acadesine treatment resulted in a reduced 
proportion of cardiac related deaths, as compared 
with placebo, which produced a statistically signifi- 
cant reduction in the acute postoperative mortality 
(p = 0.038). 
Acadesine and myocardial protection. Surgical 
and anesthetic practice is continually improving; 
however, the number of high-risk patients undergo- 
ing CABG is steadily increasing with an attendant 
rise in operative morbidity and mortality. Numerous 
attempts to preserve mYocardial viability by decreas- 
ing the effects of ischemia and reperfusion injury 
that occur during CABG have been made. Although 
many of them have been based on changes in the 
vehicle (crystalloid or blood), temperature (hypo- 
thermic or normothermic), or route or technique of 
delivery (antegrade or retrograde, intermittent or 
continuous) of cardioplegic solutions, or on appro- 
priate alterations in reperfusate composition, others 
have relied on the supplementation f cardioplegic 
or reperfusion solutions with substrates or drugs. 
Among these additives has been adenosine, the 
cardioprotective effects of which have been known 
for many years. 46'47 Interest in adenosine is cur- 
rently being renewed, partially because of its pur- 
ported role in mediating the protective ffects of 
ischemic preconditioning. 48 However, the systemic 
administration of adenosine is usually accompanied 
by unacceptable adverse vents uch as heart block, 
hypotension with reflex tachycardia, coronary steal, 
facial flushing, and dyspnea, which have limited its 
therapeutic use. The development of an adenosine- 
regulating agent such as acadesine may obviate the 
exogenous administration of adenosine, with its 
associated systemic adverse events, by enhancing 
local endogenous production or accumulation of 
adenosine. Although the mechanism by which 
acadesine may modulate local extracellular adeno- 
sine concentrations during periods of ischemia in 
animals has not been fully established, these cardio- 
protective effects are prevented when adenosine 
receptors are blocked or the formation of adenosine 
is suppressed, indicating that the ability of acadesine 
to enhance ischemia-induced a enosine l vels is the 
basis of its beneficial effects. Modulation of local 
adenosine levels in ischemic myocardium by an 
adenosine-regulating agent should be without the 
systemic adverse effects associated with exogenous 
adenosine administration, because adenosine has an 
extremely short half-life in human blood (<0.6 
second). Consequently, adenosine-regulating agents 
such as acadesine could have major clinical benefits 
in conditions in which it could prevent he progres- 
sion of myocardial ischemia to necrosis (i.e., MI), 
with its attendant morbidity and mortality. 
Methodologic considerations. The incidence of 
perioperative MI varies greatly depending on the 
criterion used for the diagnosis. However, there is 
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no consensus on the criterion by which a periopera- 
tive MI should be diagnosed inthe setting of CABG. 
In the design of this study, we recognized that 
establishing the diagnosis of an MI in the periop- 
erative period is more complicated than in the usual 
clinical setting in the ambulatory patient. The diag- 
nosis of a perioperative MI by use of only the 
occurrence of new Q waves is associated with false- 
positive and false-negative r sults. False-positive 
results occur especially with new, inferior Q waves 
resulting from the unmasking of previously undetec- 
ted infarcts. 49 False-negative r sults occur with non- 
transmural MIs. 
The design of the protocol allowed for analysis 
with two definitions used for the diagnosis of MI: 
(1) the presence of either a new Q wave on the 
ECG or elevations of CK-MB levels or a patho- 
logically confirmed myocardial necrosis at autopsy 
MI (Q wave or CK-MB, or autopsy); (2) the 
presence of both ECG changes and CK-MB ele- 
vations, or autopsy MI (Q wave and CK-MB, or 
autopsy). With the more specific and clinically 
rigorous definition (Q wave and CK-MB, or au- 
topsy), the incidence of MI was not significantly 
lower in the acadesine-treated group (5.2%) than 
in the placebo group (6.7%). Although these rates 
are compatible with those reported in the litera- 
ture, diagnosis of a perioperative MI with the 
CK-MB data was considered to be unreliable in 
this study and therefore reduced the ability to 
diagnose MI by use of any definition that included 
a CK-MB criterion. 
The unreliability of the CK-MB results is demon- 
strated in several ways. For patients with a Q wave 
who received placebo, the CK-MB concentrations 
were much lower than results reported in the liter- 
ature for similar patients having CABG in whom the 
same assay (Tandem-E CKMB II) was used. 27' 40, 44, 45 
CK-MB samples from the present study were sub- 
jected to freezing, prolonged storage, and interna- 
tional transport. The cited literature reports were all 
single center studies in which CK-MB values were 
determined on nonfrozen samples, which were pre- 
sumably assayed rapidly without being subjected to 
sample handling procedures with the potential for 
sample degradation. The CK-MB values determined 
during the validation of the CK-MB assay at the 
central aboratory for the present study on sam- 
ples obtained from nonstudy patients, including 
some with Q-wave MIs after CABG, were dramat- 
ically higher than study patient samples and were 
compatible with those reported in the literature. 45
The logistics of handling the samples in this 
multinational study could account for the discrep- 
ancies between the lower than expected values 
reported here and the data obtained during the 
CK-MB assay validation and from the other liter- 
ature reports in which the same assay kit was used. 
Additional evidence of unreliability of the 
CK-MB data comes from the fact that 50% of the 
patients with MIs confirmed anatomically at au- 
topsy did not meet the CK-MB criteria for the 
diagnosis of MI; this observation is at variance 
with a study by Van Lente and associates. 5° 
Consequently, the presence of a new Q wave or 
evidence of MI on autopsy were adopted as the 
criteria for the diagnosis of MI in this study. 
Efficacy of acadesine. Acadesine treatment did 
not significantly affect the incidence of MI in the 
overall population. The finding that acadesine sig- 
nificantly reduced the incidence of MI, with the 
Q-wave or autopsy definition used for the diagnosis, 
in high-risk patients (p = 0.032), however, is of 
potential clinical relevance, because Q-wave MIs 
have been shown to be associated with a worse 
long-term prognosis in the Coronary Artery Surgery 
Study. 15 We recognized before the start of the study 
that the high-risk patients would have a higher 
incidence of adverse outcomes and the establish- 
ment of a treatment effect in this group is not 
surprising. The lack of a statistically significant effect 
in the non-high-risk group may have resulted from a 
lower incidence of MIs in this subgroup, the occur- 
rence of false-positive Q waves associated with 
CABG, which may preclude the detection of a true 
drug effect, 5° or the presence of a lesser or no drug 
effect. Multivariate analyses demonstrated that 
acadesine treatment had a significant effect in re- 
ducing the incidence of MI in the high-risk sub- 
group, whereas the interaction between acadesine 
and parameters of surgical risk did not have a 
significant effect on MI. The type of cardioplegic 
solution used had no significant effects on outcome, 
although the sample size was insufficient to make a 
definitive conclusion. 
The incidence of combined adverse cardiovascu- 
lar outcomes was highly dependent on the incidence 
of MIs because of the lower rates for the other 
individual adverse cardiovascular outcomes. Al- 
though the rates for the combined adverse cardio- 
vascular outcomes were not different between treat- 
ments, there were potentially clinically meaningful 
reductions in the rates for cardiac death, cerebro- 
vascular accident, life-threatening arrhythmia, nd a 
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minimal reduction for left ventricular dysfunction 
with acadesine as compared with placebo. 
Results of the present study also demonstrate hat 
although the overall hospital mortality rates were 
similar in the two groups, acadesine therapy was 
associated with a lower incidence of cardiac related 
events (i.e., low output syndrome, arrhythmia, se- 
vere left ventricular dysfunction) that accounted for 
the majority of deaths occurring over the first 3 
postoperative days (placebo, 6/8; acadesine, 1/1). 
Consequently, mortality during this early postoper- 
ative period was lower in acadesine-treated, patients 
(placebo, 8/418; acadesine, 1/403; p = 0.038). 
A similarly designed study has also been con- 
ducted in the United States. 51 The results of the 
U.S. study demonstrated that acadesine decreased 
the incidence of MI, but this decrease was not 
significant according to the prospectively defined 
criteria for the diagnosis of MI (Q wave or CK-MB, 
or autopsy). However, an additional analysis that 
used a more specific definition for MI (Q wave and 
CK-MB, or autopsy) showed a statistically signifi- 
cant reduction in the incidence of MI with acadesine 
treatment (p = 0.018). 
Safety profile. This study also demonstrated that, 
for patients undergoing CABG, acadesine is safe 
when given at a dosage of 0.1 mg/kg per minute for 
7 hours in association with administration i car- 
dioplegic solutions at a final concentration of 5 
/xg/ml. Systemic blood pressure and heart rate 
showed no difference in the acadesine-treated pa- 
tients compared with the group receiving placebo. 
The overall adverse vent profile for the acadesine- 
treated patients was essentially indistinguishable 
from that of the placebo recipients. Conduction 
defects of various types were reported less fre- 
quently with acadesine or at a similar rate to pla- 
cebo. These results demonstrate hat unlike adeno- 
sine, acadesine does not lower systemic blood 
pressure or produce conduction disturbances. The 
only potential safety concern was a mild, transient 
hyperuricemia, which was maximal at the end of the 
infusion and resolved shortly thereafter, with no 
clinical sequelae. The rise in uric acid was not 
unexpected because acadesine is metabolized via 
normal purine pathways of which the end product is 
uric acid. 
Conclusions. This study has established that 
acadesine, given both intravenously during the 
perioperative period (at 0.1 mg/kg per minute over 7 
hours) and as an adjunct o cardioplegic solutions 
(at a final concentration of 5/xg/ml), is safe with an 
adverse event profile similar to that of placebo. 
Although the results of this study were not statisti- 
cally significant for the reduction of MI or hospital 
mortality in the overall population, the reduced 
incidence of MI in the high-risk subgroup, according 
to secondary Q-wave or autopsy criteria, and of 
cardiac related deaths in the acute postoperative 
period (first 3 postoperative days) suggests that 
acadesine may provide some added myocardial pro- 
tection during CABG. 
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Appendix 
The following institutions (listed in alphabetical order) 
and principal investigators participated in the Interna- 
tional Acadesine Study: 
Medical center 
Aberdeen Royal Infirmary, U.K. 
Academisch Ziekenhuis, Maastricht, 
The Netherlands 
Akademiska Sjukhuset, Uppsala, Sweden 
C.H.U. Henri M6ndor, Cr6teil, France 
C.H.U. Rangueil, Toulouse, France 
Freeman Hospital, Newcastle, U.K. 
Gasthuisberg University Clinic, Leuven, 
Belgium 
Glasgow Royal Infirmary, Glasgow, U.K. 
H6pital Augustin Morvan, Brest, France 
H6pital Broussais, Paris, France 
H6pital Lariboisi6re, Paris, France 
Institut Arnault Tzanck, Nice, France 
Klinikum Gro/3hadern, Munich, Germany 
Laval Hospital, Ste. Foy, Canada 
Middlesex Hospital, London, U.K. 
Montreal Heart Institute, Montreal, 
Canada 
National Hospital, Oslo, Norway 
Notre Dame Hospital, Montreal, Canada 
Royal Infirmary of Edinburgh, U.K. 
St. Thomas' Hospital, London, U.K. 
Toronto General Hospital, Toronto, 
Canada 
Vancouver General Hospital, Vancouver, 
Canada 
University Hospital, Lund, Sweden 
University of Alberta Hospitals, 
Edmonton, Canada 
University of Freiburg, Freiburg, 
Germany 
University of Heidelberg, Heidelberg, 
Germany 
University of Ottawa Heart Institute, 
Ottawa, Canada 
Principal 
investigator 
R. Jeffrey, 
J. Cockburn 
O. Penn 
H. E. Hansson, 
S. Thelin 
D. Loisance 
G. Fournial 
A. Hedley Brown 
W. Flameng 
W. Dimitri 
J.-A, Barra 
J.-P. Couetil 
P. Menasch6 
P. Lena 
T. Fischlein 
J. Metras 
W. Pugsley 
L. Pelletier 
O. Geiran 
N. Poirier 
C. Campanella, 
G. Sutherland 
G. Venn 
R. Weisel, 
T. David 
W. R. E. Jamieson, 
D. Ansley 
J. Kugelberg, 
S. Steen 
A. Koshal, 
E. Gelfand 
R. Seitelberger, 
R. Fasol 
S. Hagl 
P. Bedard, 
W. Keon 
The central analysis centers participating in the study were 
as follows: ECG Analysis: Queen Elizabeth Hospital, 
University of Birmingham, U.K.; M. K. Davies, S. J. S. 
Virk, H. Hamdan, and K. Kullar. Dutch Heart Scan 
Services, Maasdam, The Netherlands; H. J. Ritsema van 
Eck. CK-MB Laboratory: St. George's Hospital Medical 
School, London, U.K.; D. Holt. 
